Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Symtuza

- PMLiVE

FDA issues approval for Janssen’s HIV drug Cabenuva

The injectable treatment for adults with HIV can be administered every two months

- PMLiVE

Janssen submits marketing authorisation to EMA for teclistamab

The drug has been developed to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer

- PMLiVE

Janssen’s Tremfya receives positive results for active psoriatic arthritis

The drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies

- PMLiVE

Vir Biotech launches new research programme for HIV and malaria prevention

Using antibody research, Vir will combine its existing immunology and virology expertise with the Gates Foundation

- PMLiVE

NICE recommends long-acting HIV therapy developed by ViiV Healthcare and Janssen

People with HIV-1 in England and Wales can swap their daily tablets for a two-monthly injection regimen from 2022, joining HIV patients in Europe and the US

- PMLiVE

Janssen’s RSV vaccine provides high protection against respiratory infections

The phase 2b data showed the RSV vaccine provided 80% protection against lower respiratory infections in adults aged 65 and older

- PMLiVE

FDA nod for Janssen schizophrenia treatment Invega Hafyera

The phase 3 study results showed that 92% of patients were relapse-free after 12 months

- PMLiVE

Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit

Total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020

- PMLiVE

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Decision follows mixed results from the phase 3 ACIS study

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

- PMLiVE

Verily and Janssen to collaborate on home-based COVID-19 immune response study

Study will collect information about how COVID-19 affects the immune system

- PMLiVE

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Final analysis demonstrates a 35% reduction in the risk of death in mHSPC patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links